Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells

Ameet K. Mishra, David M Dingli

Research output: Contribution to journalArticle

Abstract

IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Molecular mechanisms regulating expression of IL-6R are not well understood and current therapies are based on monoclonal antibody to target IL-6 signaling. Small molecule inhibitors targeting IL-6 signaling are highly desirable. Metformin specifically decreased IL-6R expression which is mediated via AMPK, mTOR, and miR34a. This is a novel finding and adds to existing therapies targeting IL-6 signaling.

Original languageEnglish (US)
JournalLeukemia
DOIs
StatePublished - Jan 1 2019

Fingerprint

Metformin
Multiple Myeloma
Interleukin-6
Interleukin-6 Receptors
AMP-Activated Protein Kinases
Plasma Cells
Monoclonal Antibodies
Cytokines
Therapeutics
Growth

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. / Mishra, Ameet K.; Dingli, David M.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

@article{14d5d4775ccb4763a9c8b7b42baf77b3,
title = "Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells",
abstract = "IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Molecular mechanisms regulating expression of IL-6R are not well understood and current therapies are based on monoclonal antibody to target IL-6 signaling. Small molecule inhibitors targeting IL-6 signaling are highly desirable. Metformin specifically decreased IL-6R expression which is mediated via AMPK, mTOR, and miR34a. This is a novel finding and adds to existing therapies targeting IL-6 signaling.",
author = "Mishra, {Ameet K.} and Dingli, {David M}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0470-4",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells

AU - Mishra, Ameet K.

AU - Dingli, David M

PY - 2019/1/1

Y1 - 2019/1/1

N2 - IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Molecular mechanisms regulating expression of IL-6R are not well understood and current therapies are based on monoclonal antibody to target IL-6 signaling. Small molecule inhibitors targeting IL-6 signaling are highly desirable. Metformin specifically decreased IL-6R expression which is mediated via AMPK, mTOR, and miR34a. This is a novel finding and adds to existing therapies targeting IL-6 signaling.

AB - IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Molecular mechanisms regulating expression of IL-6R are not well understood and current therapies are based on monoclonal antibody to target IL-6 signaling. Small molecule inhibitors targeting IL-6 signaling are highly desirable. Metformin specifically decreased IL-6R expression which is mediated via AMPK, mTOR, and miR34a. This is a novel finding and adds to existing therapies targeting IL-6 signaling.

UR - http://www.scopus.com/inward/record.url?scp=85064571834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064571834&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0470-4

DO - 10.1038/s41375-019-0470-4

M3 - Article

C2 - 30988378

AN - SCOPUS:85064571834

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -